МУКОПОЛИСАХАРИДОЗ VI ТИПА (СИНДРОМ МАРОТО—ЛАМИ): КЛИНИЧЕСКИЕ ПРОЯВЛЕНИЯ, ДИАГНОСТИКА И ЛЕЧЕНИЕ

дети, мукополисахаридоз, синдром Марото—Лами, клинические проявления, диагностика, ферментозамещающая терапия, Наглазим

1. Maroteaux P., Leve^que B., Marie J., Lamy M. A new dysostosis with urinary elimination of chondroitin sulfate B. Presse Med 1963; 71: 1849–1852.

2. Neufeld E., Muenzer J. The mucopolysaccharidoses. In: Scriver C., Beaudet A., Valle D., Sly W. (eds).The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001: 3421–3452.

3. Baehner F., Schmiedeskamp C., Krummenauer F. et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 2005; 28: 1011–1017.

4. Swiedler S., Beck M., Bajbouj M. et al. Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am J Med Genet 2005; 134: 144–150.

5. Karageorgos L., Brooks D.A., Pollard A. et al. Mutational analysis of 105 mucopolysaccharidosis type VI patients. Hum Mutat 2007; 28: 9: 897–903.

6. Voskoboeva E., Isbrandt D., von Figura K. et al. Four novel mutant alleles of the arylsulfatase B gene in two patients with intermediate form of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Hum Genet 1994; 93: 3: 259–264.

7. Karageorgos L., Brooks D., Harmatz P. et al. Mutational analysis of mucopolysaccharidosis type VI patients undergoing a phase II trial of enzyme replacement therapy. Mol Genet Metab 2007; 90: 164–170.

8. Bradford T.M., Litjens T., Parkinson E.J. et al. Mucopolysaccharidosis type VI (Maroteaux- Lamy syndrome): a Y210C mutation causes either altered protein handling or altered protein function of N-acetylgalactosamine-sulfatase at multiple points in the vacuolar network. Biochemistry 2002; 41: 4962–4971.

9. Strauch O.F., Stypmann J., Reinheckel T. et al. Cardiac and ocular pathologies in a mouse model of mucopolysaccharidosis type VI. Pediat Res 2003; 54: 701–708.

10. Семячкина А.Н., Новиков П.В. Клинические проявления, лечение и социальная адаптация детей с мукополисахаридозами. Вопр соврем педиат 2004; 6: 20–24. (Syemyachkina A.N., Novikov P.V. Clinical manifestations, treatment and social adaptation of children with MPS. Vopr sovryem pediatr 2004; 6: 20–24.)

11. Giugliani R., Harmatz P., Wraith J.E. Management guidelines for mucopolysaccharidosis VI. Pediatrics 2007; 120: 405–418.

12. Simmons M.A., Bruce I.A., Penney S. et al. Otorhinolaryngological manifestations of the mucopolysaccharidoses. Int J Pediat Otorhinolaryngol 2005; 69: 589–596.

13. Semenza G., Pyeritz R. Respiratory complications of mucopolysaccharide storage disorders. Medicine (Baltimore) 1988; 67: 209–219.

14. Oudit G.Y., Butany J., Williams W.G. et al. Images in cardiovascular medicine. Left ventricular aneurysm associated with mucopolysaccharidosis type VI syndrome (Maroteaux- Lamy syndrome). Circulation 2007; 115: 60–62.

15. Azevedo A.C., Schwartz I.V., Kalakun L. et al. Clinical and biochemical study of 28 patients with mucopolysaccharidosis type VI. Clin Genet 2004; 66: 208–213.

16. Ashworth J.L., Biswas S., Wraith E., Lloyd I.C. The ocular features of the mucopolysaccharidoses. Eye 2006; 20: 553–563.

17. Van Heest A.E., House J., Krivit W., Walker K. Surgical treatment of carpal tunnel syndrome and trigger digits in children with mucopolysaccharide storage disorders. J Hand Surg 1998; 23: 236–243.

18. Schwartz G.P., Cohen E.J. Hydrocephalus in Maroteaux-Lamy syndrome. Arch Ophthalmol 1998; 116: 400.

19. Mut M., Cila A., Varli K., Akalan N. Multilevel myelopathy in Maroteaux-Lamy syndrome and review of the literature. Clin Neurol Neurosurg 2005; 107: 230–235.

20. Boor R., Miebach E., Bruhl K., Beck M. Abnormal somatosensory evoked potentials indicate compressive cervical myelopathy in mucopolysaccharidoses. Neuropediatrics 2000; 31: 122–127.

21. Albano L., Sugayama S., Bertola D. et al. Clinical and laboratorial study of 19 cases of mucopolysaccharidoses. Rev Hosp Clin Fac Med Sao Paulo 2000; 55: 213–218.

22. Whitley C.B., Ridnour M.D., Draper K.A. et al. Diagnostic test for mucopolysaccharidosis. Direct method for quantifying excessive urinary glycosaminoglycan excretion. Clin Chem 1989; 35: 374–379.

23. Hein L., Meikle P., Dean C. et al. Development of an assay for the detection of mucopolysaccharidosis type VI patients using dried blood-spots. Clin Chim Acta 2005; 353: 67–74.

24. Brooks D.A., Gibson G.J., Karageorgos L. et al. An index case for the attenuated end of the mucopolysaccharidosis type VI clinical spectrum. Mol Genet Metab 2005; 85: 236–238.

25. Dierks T., Dickmanns A., Preusser-Kunze A. et al. Molecular basis for multiple sulfatase deficiency and catalytic mechanism for formylglycine generation of the human formylglycine- generating enzyme. Cell 2005; 121: 541–552.

26. Karageorgos L., Brooks D.A., Pollar A. et al. Mutational analysis of 105 mucopolysaccharidosis type VI patients. Hum Mutat 2007; 28: 897–903.

27. Petry M.F., Nonemacher K., Sebben J.C. et al. Mucopolysaccharidosis type VI: Identification of novel mutations on the arylsulphatase B gene in South American patients. J Inherit Metab Dis 2005; 28: 1027–1034.

28. Voskoboeva E.Iu., Krasnopol'skaia K.D., Peters K., von Figura K. Identification of mutations in the arylsulfatase B gene in Russian mucopolysaccharidosis type VI patients. Genetika 2000; 36: 6: 837–843.

29. Auclair D., Hopwood J.J., Brooks D.A. et al. Replacement therapy in mucopolysaccharidosis type VI: ad-vantages of early onset of therapy. Mol Genet Metab 2003; 78: 163–174.

30. Harmatz P., Whitley C. , Waber L. et al. Enzyme replacement therapy in mucopolysac charidosis VI (Maroteaux-Lamy syndrome). J Pediat 2004; 144: 574–580.

31. Braunlin E., Rosenfeld H., Kampmann C. et al. MPS VI Study Group. Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapy. J Inherit Metab Dis 2013; 36: 2: 385–394.

32. Harmatz P., Ketteridge D., Giugliani R. et al. Direct comparison of measures of endurance, mobility, and joint function during enzymereplacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetyl-galactosamine-4-sulfatase. Pediatrics 2005; 115: 6: e681–689.

33. Sillence D., Waters K., Donaldson S. et al. Combined Enzyme Replacement Therapy and Hematopoietic Stem Cell Transplantation in Mucopolysacharidosis Type VI. JIMD Rep 2012; 2: 103–106.

34. Peters C., Steward C. Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplant 2003; 31: 229–239.

35. Staba S., Escolar M., Poe M. et al. Cord-blood transplants from unrelated donors in patients with Hurler’s syndrome. N Engl J Med 2004; 350: 1960–1969.

36. Lee V., Li C.K., Shing M.M. et al. Umbilical cord blood transplantation for Maroteaux- Lamy syndrome (mucopolysaccharidosis type VI). Bone Marrow Transplant 2000; 26: 4: 455–458.

37. Jester S., Larsson J., Eklund E.A. et al. Haploidentical stem cell transplantation in two children with mucopolysaccharidosis VI: clinical and biochemical outcome. Orphanet J Rare Dis 2013; 8: 134. doi: 10.1186/1750–1172–8–134.

38. Walker R., Allen D., Rothera M. A fibreoptic intubation tech-nique for children with mucopolysaccharidoses using the laryngeal mask airway. Paediatr Anaesth 1997; 7: 421–426.

39. Hein L., Meikle P., Dean C. et al. Development of an assay for the detection of mucopolysaccharidosis type VI patients using dried blood-spots. Clin Chim Acta 2005; 353: 67–74.